Compare CRBP & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRBP | FINW |
|---|---|---|
| Founded | 2009 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.4M | 194.4M |
| IPO Year | 2014 | 2021 |
| Metric | CRBP | FINW |
|---|---|---|
| Price | $9.27 | $14.67 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $45.50 | N/A |
| AVG Volume (30 Days) | ★ 467.9K | 33.2K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.51 |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $4,822,272.00 | N/A |
| Revenue This Year | N/A | $160.48 |
| Revenue Next Year | $116.00 | $35.27 |
| P/E Ratio | ★ N/A | $74.00 |
| Revenue Growth | ★ 97.62 | N/A |
| 52 Week Low | $7.12 | $12.82 |
| 52 Week High | $20.56 | $22.49 |
| Indicator | CRBP | FINW |
|---|---|---|
| Relative Strength Index (RSI) | 57.06 | 48.81 |
| Support Level | $7.42 | $13.06 |
| Resistance Level | $9.57 | $14.90 |
| Average True Range (ATR) | 0.50 | 0.52 |
| MACD | 0.21 | 0.03 |
| Stochastic Oscillator | 87.14 | 39.37 |
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and commercial customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.